Hypoxia, angiogenesis and liver fibrogenesis in the progression of chronic liver diseases by Paternostro, Claudia et al.
EDITORIAL
Hypoxia, angiogenesis and liver fibrogenesis in the 
progression of chronic liver diseases
Claudia Paternostro, Ezio David, Erica Novo, Maurizio Parola
Claudia Paternostro, Erica Novo, Maurizio Parola, Department 
of Experimental Medicine and Oncology, Interuniversity Centre 
for Hepatic Pathophysiology, University of Torino, Corso 
Raffaello 30, 10125 Torino, Italy
Ezio David, Department of Pathology, San Giovanni Battista 
Hospital, 10126 Torino, Italy
Author contributions: Paternostro C, David E, Novo E, and 
Parola M equally contributed to this paper. 
Correspondence to: Maurizio Parola, PhD, Professor, Depart­
ment of Experimental Medicine and Oncology, Interuniversity 
Centre for Hepatic Pathophysiology, University of Torino, Corso 
Raffaello 30, 10125 Torino, Italy. maurizio.parola@unito.it 
Telephone: +39­11­6707772   Fax: +39­11­6707753
Received: October 17, 2009   Revised: December 11, 2009
Accepted: December 18, 2009
Published online: January 21, 2010 
Abstract
Angiogenesis is a dynamic, hypoxia-stimulated and 
growth factor-dependent process, and is currently 
referred to as the formation of new vessels from pre-
existing blood vessels. Experimental and clinical stud-
ies have unequivocally reported that hepatic angiogen-
esis, irrespective of aetiology, occurs in conditions of 
chronic liver diseases (CLDs) characterized by perpetu-
ation of cell injury and death, inflammatory response 
and progressive fibrogenesis. Angiogenesis and related 
changes in liver vascular architecture, that in turn con-
cur to increase vascular resistance and portal hyper-
tension and to decrease parenchymal perfusion, have 
been proposed to favour fibrogenic progression of the 
disease towards the end-point of cirrhosis. Moreover, 
hepatic angiogenesis has also been proposed to modu-
late the genesis of portal-systemic shunts and increase 
splanchnic blood flow, thus potentially affecting com-
plications of cirrhosis. Hepatic angiogenesis is also cru-
cial for the growth and progression of hepatocellular 
carcinoma. Recent literature has identified a number 
of cellular and molecular mechanisms governing the 
cross-talk between angiogenesis and fibrogenesis, 
with a specific emphasis on the crucial role of hypoxic 
conditions and hepatic stellate cells, particularly when 
activated to the myofibroblast-like pro-fibrogenic phe-
notype. Experimental anti-angiogenic therapy has been 
proven to be effective in limiting the progression of 
CLDs in animal models. From a clinical point of view, 
anti-angiogenic therapy is currently emerging as a new 
pharmacologic intervention in patients with advanced 
fibrosis and cirrhosis. 
© 2010 Baishideng. All rights reserved.
Key words: Chronic liver diseases; Hepatic myofibrob-
lasts; Hypoxia; Liver angiogenesis; Liver fibrogenesis
Peer reviewer: Devanshi Seth, PhD, Senior Scientist, Centenary 
Institute & Drug Health Services, RPAH & Clinical Senior 
Lecturer, Clinical School of Medicine, University of Sydney, 
Camperdown, NSW 2050, Australia
Paternostro C, David E, Novo E, Parola M. Hypoxia, angiogen­
esis and liver fibrogenesis in the progression of chronic liver 
diseases. World J Gastroenterol 2010; 16(3): 281­288  Available 
from: URL: http://www.wjgnet.com/1007­9327/full/v16/i3/
281.htm  DOI: http://dx.doi.org/10.3748/wjg.v16.i3.281
INTRODUCTION
Angiogenesis can be envisaged as a dynamic, hypoxia-
stimulated and growth factor-dependent ubiquitous 
process leading to the formation of  new vessels from 
pre-existing blood vessels[1-5], and should be distinguished 
from other terms that, although related to vessel 
formation and growth, define significantly different 
processes such as vasculogenesis, arteriogenesis and 
collateral vessel growth. Angiogenesis occurs virtually in 
almost all organs and tissues and is considered a critical 
step in either physiological conditions or in tissue repair 
and growth in several pathophysiological conditions[1-5], 
including chronic liver diseases (CLDs)[6-8]. 
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Where the liver is concerned, physiological and patho-
logical angiogenesis can occur during liver regeneration 
(after acute liver injury or after partial hepatectomy), 
in ischemic conditions, during chronic inflammatory 
and fibrogenic liver diseases as well as in hepatocellular 
carcinoma and in metastatic liver cancers[6-8]. The steps 
and mechanisms of  hepatic angiogenesis mostly overlap 
with those described in other organs or tissues but a 
number of  liver parenchyma peculiarities are likely to 
make the overall scenario more complex[6]. These include 
the existence of  two different kinds of  microvascular 
structures (portal vessels and liver sinusoids, lined by conti-
nuous or fenestrated and discontinuous endothelium, 
respectively), the expression of  a putative liver specific 
angiopoietin-like peptide defined as ANGPTL3[9] and, 
most relevant, the unique and heterogenous phenotypic 
profile and functional role of  hepatic stellate cells 
(HSCs) that, although regarded as liver specific pericytes 
in normal liver, also represent the most relevant pro-
fibrogenic cell lineage[10-13] in CLDs. HSCs, particularly in 
their activated and myofibroblast-like phenotype (HSC/
MFs), are indeed emerging as cells that may have an 
active role in modulating angiogenesis that differs from 
the one attributed to microcapillary pericytes[14]. The 
overall scenario is even more complex if  one considers 
that in CLDs hepatic myofibroblast-like cells (MFs) 
constitute a heterogenous population of  pro-fibrogenic 
cells. These highly proliferative and contractile cells 
may also originate from portal (myo) fibroblasts, bone 
marrow-derived stem cells and, as recently suggested, 
also from hepatocytes or cholangiocytes through a pro-
cess of  epithelial to mesenchymal transition[10-13]. In the 
following section of  this editorial we will try to focus 
on those relevant features that link angiogenesis to 
liver fibrogenesis and then the progression of  CLDs. 
The interested reader can refer to more comprehensive 
reviews - such as articles with more details on the basic 
principles and mechanisms involved in angiogenesis as 
well as the analysis of  the role of  angiogenesis in liver 
regeneration or hepatocellular carcinoma[10-14].
HEPATIC ANGIOGENESIS AND ITS 
RELATIONSHIPS BETWEEN CHRONIC 
INFLAMMATION AND FIBROGENIC 
PROGRESSION OF CLDs
CLDs are characterized by reiteration of  liver injury 
due to a number of  aetiological conditions, including 
chronic infection by viral agents [mainly hepatitis B virus 
(HBV) and hepatitis C virus (HCV)] as well as metabolic, 
toxic/drug-induced (with alcohol consumption being 
predominant) and autoimmune causes, resulting in 
persistent inflammation and progressive fibrogenesis. 
Chronic activation of  the wound healing response is 
the major driving force for progressive accumulation of  
extracellular matrix (ECM) components, eventually leading 
to liver cirrhosis and hepatic failure. Oxidative stress and 
redox signalling, derangement of  epithelial-mesenchymal 
interactions or, as recently proposed, the process of  
epithelial to mesenchymal transition represent additional 
mechanisms able to sustain fibrogenesis progression 
towards the final end-point of  cirrhosis[11,12,15-17]. 
Along these lines, cirrhosis should be regarded 
as an advanced stage of  fibrosis characterized by the 
formation of  regenerative nodules of  parenchyma, 
surrounded and separated by fibrotic septa, and asso-
ciated with significant changes in angio-architecture. 
The suggestion that angiogenesis may significantly 
contribute to fibrogenesis and disease progression relies 
first on the fact that vascular remodelling, irrespective 
of  aetiology, is a common finding in human cirrhotic 
livers[11,12,14,18,19]. Moreover, the formation of  fibrotic 
septa, as well as capillarization of  sinusoids, the latter 
due to early deposition of  fibrillar ECM in the space 
of  Disse, can result in an increased resistance to blood 
flow and oxygen delivery. These are the premises for 
hypoxia and the transcription of  hypoxia-sensitive pro-
angiogenic genes, usually modulated by the so-called 
hypoxia inducible factors (HIFs)[20-23]. In addition, it is 
well known that in CLDs the inflammatory response 
gains the role of  a dynamic state relevant for the pro-
gression of  fibrogenesis towards the end-point of  
cirrhosis[11-13,16]. Several mediators of  the inflammatory 
response may stimulate other cells in the surrounding 
microenvironment to express vascular endothelial growth 
factor (VEGF) and other pro-angiogenic factors as well 
as to sustain angiogenesis[24]. Moreover, cytokines or 
mediators produced during CLDs such as hepatocyte 
growth factor (HGF), platelet-derived growth factor 
(PDGF) and nitric oxide (NO), can play a role in the 
development of  angiogenesis[6,13,14]. In particular, one 
should consider that: (1) neo-vessels themselves can 
significantly contribute to perpetuation of  the inflam-
matory response by expressing chemokines and adhesion 
molecules promoting the recruitment of  inflammatory 
cells; (2) angiogenesis, early in the course of  a CLD, 
may contribute to the transition from acute to chronic 
inflammation[25].
A relevant additional point, as recently proposed[20], 
is that depending on the specific pattern of  fibrosis 
(post-necrotic or bridging fibrosis, pericellular or 
perisinusoidal fibrosis, biliary fibrosis or centrilobular 
fibrosis)[12,26], the extent of  neo-angiogenesis, in addition 
to favouring disease progression, may also represent 
a key limiting factor for fibrosis reversibility. This is 
potentially relevant for post-necrotic or bridging fibrosis, 
a pattern which is mainly seen in patients with advanced 
fibrosis or cirrhosis by chronic HBV or HCV infection. 
In this pattern of  fibrosis, which is characterized by the 
formation of  bridging septa between portal and central 
vein areas, angiogenesis, vascular remodelling and altered 
angio-architecture are particularly impressive. 
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PATHOLOGICAL ANGIOGENESIS AND 
PRO-ANGIOGENIC CYTOKINES HAVE 
BEEN DETECTED IN HUMAN CLDs
Current evidence suggests that angiogenesis and fib-
rogenesis are detectable and develop in parallel in any 
clinical condition of  CLDs that can progress towards the 
end-point of  cirrhosis, irrespective of  aetiology, as well as 
in the most widely used experimental animal models of  
CLDs[6,13,19,20]. 
Where clinical data are concerned, best relationships 
between angiogenesis and the pattern of  fibrosis (i.e. 
bridging fibrosis)[12,26] are usually found during chronic 
viral infection by either HBV or HCV. This is documented 
by either the abundant presence of  endothelial cells (ECs) 
and neovessels/capillary structures found in inflamed 
portal tracts[6] or by the over-expression of  major pro-
angiogenic molecules, including VEGF and Angiopoietin 
1 (Ang-1) as well as their related receptors (VEGFR type 
Ⅱ, Tie2) and HGF[27-31]. In these clinical settings, PDGF, 
which is released by periportal inflammatory cells as well 
as by sinusoidal and perisinusoidal cells, may also play a 
pro-angiogenic role[32]. In addition, selected viral proteins 
may have a multiple pro-angiogenic role like HBV-related 
X protein[33]. This protein has been involved in disruption 
of  inter-endothelial junctions by operating through a src-
kinase-dependent signalling pathway, as well as in the 
up-regulation of  inducible nitric oxide synthase (iNOS) 
through involvement of  nuclear factor-κB (NF-κB) 
transcription factor[34] or even by up-regulating membrane-
type matrix metalloprotease (MT-MMP) expression, and 
then MMP-2 activation in hepatocytes[35].
Angiogenesis has also been detected in biopsies 
from patients affected by either primary biliary cirrhosis 
(PBC) or autoimmune hepatitis as formation of  neo-
vessels by ECs positive for CD-31 and vascular endo-
thelial-cadherin[6]. These neo-vessels were located, 
particularly in PBC, mainly in portal areas in association 
with inflammatory infiltrate[6,36]. Once again, enhanced 
expression of  angiogenic molecules such as VEGF, 
Ang-1, Ang-2, Tie-2 and endoglin has also been 
characterized in these PBC patients. 
Similar data have been reported for the most widely 
used experimental animal models of  CLDs that have 
been instrumental in unequivocally documenting that 
angiogenesis and fibrogenesis develop in parallel during 
progression towards cirrhosis[31,37-43]. 
Both human and experimental studies have also 
outlined that several peptide mediators other than VEGF, 
Ang-1 and HGF are likely to be involved in hepatic 
angiogenesis associated with the fibrogenic progression 
process in CLDs. Unequivocal data have been provided 
for the pro-angiogenic action of  PDGF[32] as well as for 
leptin, an adipocytokine that has been suggested to exert 
a pro-fibrogenic effect in promoting the development 
from non-alcoholic fatty liver disease (NAFLD) to non-
alcoholic steatohepatitis (NASH)[40,44]. Where leptin is 
concerned, it has been shown that leptin can up-regulate 
the expression of  VEGF and Ang-1, as well as the pro-
inflammatory chemokine monocyte chemoattractant 
protein 1 or MCP-1[44]. The role of  angiogenesis in NASH 
development and fibrosis has been confirmed by a study 
performed on Zucker rats, animals that naturally develop 
leptin receptor mutations[40], receiving the steatogenous 
choline-deficient and amino acid defined (CDAA) diet. 
THE EMERGING ROLE OF HYPOXIA IN 
FIBROGENIC CLDs 
Another major message coming mainly from experi-
mental models of  CLDs is that VEGF overexpression is 
strictly associated with hypoxic areas and is mostly lim-
ited to hepatocytes as well as to HSC/MFs[31,37-43]. This 
concept fits well with the rational hypothesis that hy-
poxia is likely to represent the major stimulus for hepatic 
angiogenesis. The colocalization of  hypoxic areas with 
VEGF overexpression and/or the association between 
VEGF expression and progression of  fibrogenesis was 
first described in the model of  bile duct ligation (BDL)[37] 
and then confirmed in the diethyl-nitrosamine (DEN) 
model of  fibrosis[38], in the model of  chronic treatment 
with CCl4[31,39,41] and in the choline-deficient and amino 
acid-defined diet rat model of  NAFLD evolving into 
NASH and significant fibrosis[40]. Of  relevance, a recent 
study, has outlined in a mechanistic way, the strict rela-
tionships between hypoxia, angiogenesis, inflammation 
and fibrogenesis by using liver conditional HIF-1α-
deficient mice that were subjected to the BDL model 
of  fibrosis[43]. In this study, it was clearly shown that the 
appearance of  HIF-1α-positive hypoxic areas in the liver 
of  BDL mice can take place as early as 3 d after surgery, 
before the development of  detectable signs of  fibrosis. 
In particular, within hypoxic areas HIF-1α was found to 
be activated in hepatocytes and Kupffer cells. HIF-1α -/- 
conditional mice subjected to BDL were characterized by 
a very significant decrease in collagen type Ⅰ and α-SMA 
transcripts and protein levels, as well as of  transcripts 
for PDGF-A, PDGF-B, plasminogen activator inhibi-
tor-1 (PAI-1) and fibroblast growth factor 2 (FGF-2) as 
compared to wild type mice in which the typical scenario 
of  biliary-type fibrosis and cirrhosis was associated with 
early and sustained up-regulation of  HIF-1α[43]. The au-
thors of  this study proposed that hypoxic hepatocytes, 
following activation of  HIF-1α and through the HIF-
1α-dependent release of  these growth factors and medi-
ators, may significantly contribute to either initial repair 
and revascularization of  injured parenchyma as well as to 
fibrosis progression by targeting profibrogenic MFs. In a 
more recent study from the same group, this hypothesis 
was further investigated by exposing to hypoxia cultured 
hepatocytes obtained from normal mice as well as from 
HIF-1α or HIF-1β deficient mice[23]. The overall sce-
nario which emerged from the latter study indicated that 
hypoxic hepatocytes, through the involvement of  HIF-
1α and HIF-2α, can express and release PAI-1, VEGF 
and the vasoactive peptides adrenomedullin-1 (ADM-1) 
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and ADM-2[23]. Hepatocytes exposed to hypoxia during 
CLD progression are then reasonably a relevant source 
of  vasoactive mediators as well as of  the master pro-
angiogenic cytokine VEGF. This unavoidably underlines 
the relevance of  the cross-talk between hypoxic hepato-
cytes and surrounding non-parenchymal cells like sinu-
soidal endothelial cells (SECs) and, as we will see later in 
this editorial, activated MFs. Indeed, VEGF has a well 
known major pro-angiogenic role by increasing vascular 
permeability as well as triggering endothelial cell prolif-
eration and regulating neo-vessel lumen diameter[1-8,14,19]. 
Along these lines, it is worth mentioning that in the 
rat model of  chronic administration of  CCl4, hypoxic 
hepatocytes have also been shown to contribute to the 
expression of  the master profibrogenic cytokine trans-
forming growth factor-β1 (TGF-β1)[45]. This contribution 
has been reported to be relevant mainly in an advanced 
stage of  fibrosis or cirrhosis, whereas TGF-β1 is mainly 
produced by MFs and activated macrophages during early 
fibrosis and middle stage fibrogenic progression[45]. 
A strict association between hypoxia and liver fibro-
genesis can also be easily appreciated in the liver of  human 
HCV cirrhotic patients by detecting HIF-2α and α-SMA 
in serial sections (Figure 1). HIF-2α-positive staining in 
these human specimens is usually detectable in hepatocytes 
of  pseudolobules as well as in some MFs at the interface 
between fibrotic septa and liver parenchyma or even within 
pseudolobules. Moreover, it is also evident that α-SMA-
positive MFs are in close contact with HIF-2α positive 
hepatocytes. Along these lines, it has been suggested 
that hypoxia may result in VEGF- and Angiopoietin 
1-dependent increased migration and chemotaxis of  HSC/
MFs, contributing to their recruitment towards the site of  
injury and alignment with both nascent and established 
fibrotic septa, a relevant pro-fibrogenic feature[31]. 
Hypoxia has also been suggested to result in the 
down-regulation of  HGF expression by HSCs and in the 
inhibition of  c-met expression by hepatocytes[46], both 
events being able to significantly contribute to depressed 
liver regeneration during chronic liver injury. 
THE ROLE OF PROFIBROGENIC CELLS IN 
LIVER ANGIOGENESIS 
Hepatic stellate cells, due to their strategic location in the 
space of  Disse and intimate contact with sinusoidal ECs, 
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Figure 1  Immunohistochemical analysis performed on paraffin liver sections from patients with hepatitis C virus (HCV)-related liver cirrhosis (METAVIR 
F4). Sections (2 μm thick) were incubated with specific antibodies raised against HIF-2α or α-SMA that positively stain cells exposed to hypoxia (HIF-2α) or 
myofibroblast-like cells (α-SMA). Primary antibodies were labelled by using EnVision, HRP-labelled System (DAKO) antibodies and visualized by 3’-diaminobenzidine 
substrate. Negative controls (C neg) were obtained by replacing the respective primary antibodies by isotype and concentrations matched irrelevant antibody. Original 
magnification is indicated.
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have been described to behave as liver specific pericytes 
and then to play a role in physiological angiogenesis[10]. 
Recent literature data suggest that HSC/MFs in CLDs 
are likely to represent a hypoxia-sensitive and cyto- and 
chemokine-modulated cellular crossroad between necro-
inflammation, pathological angiogenesis and fibrogenesis. 
The latter statement is strongly suggested, in addition 
to exhaustive literature that has characterized the pro-
fibrogenic and pro-inflammatory role of  these cells, 
by a series of  studies that outlined the following major 
concepts: (1) HSC and HSC/MFs can behave as pro-
angiogenic cells able to react to conditions of  hypoxia by 
up-regulating transcription and synthesis of  VEGF, Ang-1 
and their related receptors VEGFR-2 and Tie2[31,44,47,48]; the 
same behaviour has also been described for human HSC/
MFs in which leptin was able to trigger a ERK1/2 and 
PI3-K-dependent nuclear translocation of  HIF-1α[44]; (2) 
HSC/MFs also represent a cellular “target” for the action 
of  VEGF and Angiopoietin 1; VEGF has been reported 
to be able to trigger HSC/MFs proliferation[39,49,50], increase 
deposition of  ECM components[38,39,50], as well as increase 
migration and chemotaxis[31]. 
This is a scenario that is likely to be relevant in the 
progression of  a CLD, as shown recently by in vivo 
morphological data obtained in human and rat fibrotic/
cirrhotic livers[31]. α-SMA-positive MFs, able to express 
concomitantly VEGF, Ang-1 or the related receptors 
VEGFR-2 and Tie-2, are found at the leading edge of  
tiny and incomplete developing septa, but not in larger 
bridging septa. This distribution may reflect the existence 
of  two different phases of  the angiogenic process during 
CLDs: an early phase, occurring in developing septa, 
in which fibrogenesis and angiogenesis may be driven/
modulated by HSC/MFs, and a later phase occurring in 
larger and more mature fibrotic septa where the chronic 
wound healing is less active and fibrogenic transformation 
more established. In such a late setting, pro-angiogenic 
factors are expressed only by endothelial cells, a scenario 
that is likely to favour stabilization of  the newly formed 
vessels. 
A very recent and elegant experimental study[51] has 
outlined another putative pro-angiogenic mechanism, 
that may have a role in vascular remodelling in cirrhosis. 
This mechanism is related to the action of  so-called 
microparticles Hedgehog (Hh) ligands, which are known 
to be released during embryogenesis and to activate Hh 
signalling in endothelial cells. In this study, the authors 
showed that cholangiocytes and HSC/MFs can produce 
and then release, mainly in response to PDGF, Hh 
ligands in microparticles and that this event is relevant 
under conditions leading to experimental biliary cirrhosis 
(BDL model). The authors propose the following 
scenario: (1) in normal conditions the action of  the low 
amount of  Hh ligand released by rare immature ductular-
type progenitors is counteracted by expression of  Hh 
interacting protein (HIP) expressed by either quiescent 
HSC or fenestrated SEC; (2) under conditions of  chronic 
injury, HIP expression is repressed and activation of  
ductular-type progenitor cells may result in PDGF-BB 
up-regulation and release; this, in turn, is likely to lead 
HSC/MFs and ductular cells to produce Hh ligands. Hh 
ligands, apart from promoting proliferation and survival 
of  both cholangiocytes and HSC/MFs, may also promote 
changes in SEC gene expression resulting in capillarization 
of  sinusoids and the release of  vasoactive factors such as 
nitric oxide, then contributing to vascular remodelling in 
cirrhosis[51]. 
PATHOLOGICAL ANGIOGENESIS AS A 
POTENTIAL THERAPEUTIC TARGET IN 
CLDs
The analysis of  the data and concepts presented in the 
previous sections, concerning the proposed relationships 
between angiogenesis, chronic wound healing and 
fibrogenesis and then disease progression, unavoidably 
leads to the following theoretical clinical goals: (1) 
detection of  selected pro-angiogenic molecules (i.e. in 
serum or plasma) may serve as a non-invasive way to 
monitor both disease progression as well as the response 
to therapy; (2) anti-angiogenic therapy may be an effective 
tool for blocking or slowing down fibrogenic progression 
of  CLDs. 
We are indeed far from the first goal, and at present 
just a single study performed on 36 chronic HCV 
patients (vs 15 healthy controls) has tried to correlate 
circulating levels of  molecules related to angiogenesis, 
disease progression and efficacy of  standard pegylated 
interferon α-2b (IFN-α2b) plus ribavirin therapy. VEGF, 
Ang-2 and soluble Tie-2 (sTie-2) were determined 
in the serum before and after therapy and authors 
reported increased levels of  VEGF and Ang-2 that were 
significantly decreased after therapy in these patients[52]. 
 Where the efficacy of  the angiogenic therapy is 
concerned, experimental data unequivocally indicate that 
anti-angiogenic therapy is indeed effective in preventing 
progressive fibrogenesis. Pioneering studies employed 
anti-angiogenic molecules or drugs like the semi-synthetic 
analogue of  fumagillin TNP-470[53] or antibodies able 
to neutralize either VEGFR-1 (Flt-1) and/or VEGFR-2 
(Flk-1)[39], both conditions being able to significantly 
inhibit angiogenesis, the number of  α-SMA-positive cells 
and the development of  fibrosis. The latter study also 
showed the in vivo predominance of  VEGF interaction 
with VEGFR-2 to mediate angiogenesis during chronic 
liver injury. Neutralizing antibodies against VEGFR-2 
were employed in other relevant studies, performed 
on a model of  portal hypertensive rats, where VEGF 
expression and related angiogenesis were correlated to 
the development of  porto-systemic collateral vessels 
and hyperdynamic splanchnic circulation[54,55]. These data 
suggest that the increase in portal blood flow, which is an 
important contributor to portal hypertension, depends 
not only on vasodilation, but also on the enlargement of  
the splanchnic vascular tree caused by angiogenesis. 
More recently, positive results have been obtained 
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in the chronic CCl4 rat model of  CLD by employing 
Sunitinib, a tyrosine kinase receptor inhibitor able to 
target VEGF and PDGF receptors[41]. The treatment of  
cirrhotic animals with Sunitinib resulted in a significant 
decrease in hepatic vascular density, inflammatory 
infiltrate, abundance of  α-SMA-positive mesenchymal 
cells, ECM deposition and even portal pressure. 
Positive results have been also reported in another 
recent study in which mice undergoing BDL or chronic 
CCl4 treatment received an adenovirus expressing soluble 
Tie-2 (AdsTie-2), the receptor for Ang-1, resulting in 
the blocking of  Ang-1 signalling and in a significant 
prevention of  both angiogenesis and fibrosis[42]. 
A final and very recent experimental study reported 
a beneficial effect of  Sorafenib[56], a receptor tyrosine 
kinase inhibitor already approved for the treatment of  
hepatocellular carcinoma[57,58], one of  the most common 
complications of  liver cirrhosis. In this study, oral admini-
stration of  Sorafenib in rats with portal hypertension and 
cirrhosis (once a day for 2 wk) resulted in the inhibition 
of  VEGF, PDGF and Raf  kinase signalling; this, in turn, 
resulted in an approximately 80% decrease in splanchnic 
neovascularization and a very significant attenuation of  
hyperdynamic splanchnic and systemic circulations, as well 
as a significant decrease in the extent of portosystemic 
collaterals. Of  relevance, Sorafenib treatment in cirrhotic 
rats also led to a 25% reduction in portal pressure and to a 
relevant improvement in liver injury, inflammation, fibrosis 
and angiogenesis.
The latter study has raised, in a more compelling way, 
the obvious question of  whether anti-angiogenic therapy 
has an adequate rationale to be seriously considered for 
therapy in patients with cirrhosis and portal hypertension. 
As nicely pointed out by Shah and Bruix[59], any future 
clinical trial employing Sorafenib in cirrhotic patients should 
assess a number of  critical issues, the first being the optimal 
dosage to be used which may be theoretically lower than 
the dosage used in patients with hepatocellular carcinoma 
(HCC). The adverse effects of  Sorafenib may represent a 
relevant concern: it is already known that more than 40% 
of  HCC patients are forced to interrupt treatment[57,58], and 
it has been shown that a major complication of  angiogenic 
treatments employing Bevacizumab and Sunitinib in 
HCC patients is variceal bleeding[60,61]. Although available 
data indicate that Sorafenib may be relatively safe in this 
complication, caution is in any case necessary because it 
has been authoritatively suggested that an intense anti-
angiogenic effect may lead to significant damage of  the vasa 
vasorum needed to maintain the structure of  varices[59]. 
Another note of  caution has recently been provided 
by an experimental study performed in order to assess 
the anti-fibrotic potential of  the inhibition of  the 
vitronectin receptor integrin αvβ3, which has been shown 
to both promote angiogenesis by mediating migration 
and proliferation of  SECs as well as to drive fibrogenic 
activation of  HSCs[62]. These authors employed the 
specific inhibitor of  integrin αvβ3, Cilengitide which 
was administered orally in two different animal models 
of  liver fibrosis, BDL and chronic administration of  
thioacetamide (TAA). The relevant point was that this 
treatment was very effective in decreasing the overall 
formation of  neo-vessels in both portal areas of  BDL and 
septal areas of  TAA fibrotic rats. Unfortunately, despite 
the anti-fibrogenic in vitro effect exerted by Cilengitide on 
cultured HSC/MFs, in vivo treatment with this inhibitor 
was associated in both models with a significant increase 
in liver collagen deposition and up-regulation of  other 
profibrogenic genes and of  matrix metalloproteinase-13, 
that is an overall worsening of  liver fibrosis, with no 
relevant effect on inflammatory response[62]. 
The use of  anti-angiogenic drugs and, in particular, 
those drugs which have already been approved for the 
treatment of  HCC, may then represent an attractive 
alternative therapeutic tool to prevent or significantly slow 
down fibrosis progression towards cirrhosis, which also 
represents the main risk factor for liver cancer development, 
as well as the development of  portal hypertension and its 
complications. However, a tempered final message is that 
angiogenesis inhibitors should be used with caution and 
carefully balanced in these patients, bearing in mind that 
angiogenesis unavoidably is a relevant event for wound 
healing and excessive blocking of  angiogenesis may not 
represent the desired therapeutic objective. Clinical trials 
with an appropriate design and primary end-points are 
needed.
CONCLUSION
Hepatic angiogenesis has been unequivocally described in 
CLDs, irrespective of  aetiology, and in the most reliable 
experimental models of  liver fibrosis and cirrhosis. 
Angiogenesis and related changes in angio-architecture 
have been proposed to favour fibrogenic progression of  
the disease towards the end-point of  cirrhosis. Moreover, 
in CLDs these changes are believed to be involved in the 
increase of  vascular resistance and portal hypertension 
as well as in the decrease of  parenchymal perfusion. At 
the same time, hepatic angiogenesis has been proposed 
to modulate the genesis of  portal-systemic shunts and 
increase splanchnic blood flow, potentially affecting 
complications of  cirrhosis. Hypoxia and HIFs-related 
cellular responses are emerging as crucial in the overall 
scenario of  CLD progression. Several cellular and 
molecular mechanisms have been identified which regulate 
the cross-talk between angiogenesis and fibrogenesis as 
well as between the different hepatic cell populations. In 
this scenario a major role is played by hypoxic hepatocytes, 
sinusoidal endothelial cells as well as hepatic MFs. Where 
MFs are concerned, whatever their origin, they are 
currently believed to represent a crucial cellular cross-road 
at the intersection between inflammation, angiogenesis 
and fibrogenesis. Indeed, these profibrogenic and pro-
inflammatory cells also represent a cellular target for the 
action of  pro-angiogenic cytokines as well as an effective 
source of  VEGF and Ang-1. 
Finally, experimental anti-angiogenic therapy has 
proven to be very effective in limiting the fibrogenic 
progression of  animal models of  CLDs. The use of  
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anti-angiogenic drugs, particularly of  those that have 
already been approved for HCC therapy like Sorafenib, 
may then represent a rationale therapeutic option to limit 
the progression of  human CLDs towards cirrhosis and 
its complications, including the development of  HCC. 
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